1. Home
  2. TECX vs BCAR Comparison

TECX vs BCAR Comparison

Compare TECX & BCAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tectonic Therapeutic Inc.

TECX

Tectonic Therapeutic Inc.

HOLD

Current Price

$33.31

Market Cap

393.0M

Sector

N/A

ML Signal

HOLD

BCAR

D. Boral ARC Acquisition I Corp. Class A Ordinary Shares

N/A

Current Price

$10.11

Market Cap

419.8M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
TECX
BCAR
Founded
2019
2025
Country
United States
United States
Employees
51
N/A
Industry
Blank Checks
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
393.0M
419.8M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
TECX
BCAR
Price
$33.31
$10.11
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$80.40
N/A
AVG Volume (30 Days)
380.4K
154.1K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.70
$9.89
52 Week High
$35.99
$10.65

Technical Indicators

Market Signals
Indicator
TECX
BCAR
Relative Strength Index (RSI) 67.84 45.30
Support Level $16.83 $10.08
Resistance Level $35.99 $10.65
Average True Range (ATR) 2.81 0.02
MACD 0.91 0.00
Stochastic Oscillator 80.72 50.00

Price Performance

Historical Comparison
TECX
BCAR

About TECX Tectonic Therapeutic Inc.

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

About BCAR D. Boral ARC Acquisition I Corp. Class A Ordinary Shares

D Boral ARC Acquisition I Corp is a blank check company.

Share on Social Networks: